The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats

European Journal of Pharmacology

Volumn 633, Issue 1-3, 2010, Pages 55-61

  Prins, Jolanda ^a   Denys, Damiaan A ^b   Westphal, Koen G ^a   Korte Bouws, Gerdien A ^a   Quinton, Maria S ^c   Schreiber, Rudy ^c   Groenink, Lucianne ^a   Olivier, Berend ^a,d   Korte, S Mechiel ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c SUNOVION PHARMACEUTICALS INC   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; DOV 216,303; In vivo microdialysis; Monoamine transporter; Olfactory bulbectomy; Racemate

Indexed keywords

1 (3,4 DICHLOROPHENYL) 3 AZABICYCLO[3.1.0]HEXANE; ANTIDEPRESSANT AGENT; DOPAMINE; MONOAMINE; NORADRENALIN; SEROTONIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MICRODIALYSIS; MONOAMINE RELEASE; NEUROTRANSMISSION; NONHUMAN; NORADRENALIN RELEASE; OLFACTORY BULBECTOMY; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SEROTONIN RELEASE; SINGLE DRUG DOSE;

ANIMALS; ANTIDEPRESSIVE AGENTS; AZA COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; DEPRESSIVE DISORDER, MAJOR; DISEASE MODELS, ANIMAL; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; MALE; NOREPINEPHRINE; OLFACTORY BULB; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 77949917850     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.02.009     Document Type: Article

References (29)

1. Blier P., de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 1994, 15:220-226.
2. Breuer M.E., Groenink L., Oosting R.S., Westenberg H.G., Olivier B. Long-term behavioral changes after cessation of chronic antidepressant treatment in olfactory bulbectomized rats. Biol. Psychiatry 2007, 61:990-995.
3. Breuer M.E., Chan J.S., Oosting R.S., Groenink L., Korte S.M., Campbell U., Schreiber R., Hanania T., Snoeren E.M., Waldinger M., Olivier B. The triple monoaminergic reuptake inhibitor DOV 216, 303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects. Eur. Neuropsychopharmacol. 2008, 18:908-916.
4. Casanovas J.M., Lesourd M., Artigas F. The effect of the selective 5-HT1A agonists alnespirone (S-20499) and 8-OH-DPAT on extracellular 5-hydroxytryptamine in different regions of rat brain. Br. J. Pharmacol. 1997, 122:733-741.
5. Casanovas J.M., Hervas I., Artigas F. Postsynaptic 5-HT1A receptors control 5-HT release in the rat medial prefrontal cortex. Neuroreport 1999, 10:1441-1445.
6. Croom K.F., Perry C.M., Plosker G.L. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs 2009, 23:427-452.
7. Demyttenaere K., Jaspers L. Review: bupropion and SSRI-induced side effects. J. Psychopharmacol. 2008, 22:792-804.
8. Dunlop B.W., Nemeroff C.B. The role of dopamine in the pathophysiology of depression. Arch. Gen. Psychiatry 2007, 64:327-337.
9. Henry C., Demotes-Mainard J. SSRIs, suicide and violent behavior: is there a need for a better definition of the depressive state?. Curr. Drug Saf. 2006, 1:59-62.
10. Kelly J.P., Wrynn A.S., Leonard B.E. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol. Ther. 1997, 74:299-316.
11. Kinney G.G., Taber M.T., Gribkoff V.K. The augmentation hypothesis for improvement of antidepressant therapy: is pindolol a suitable candidate for testing the ability of 5HT1A receptor antagonists to enhance SSRI efficacy and onset latency? Mol. Neurobiol. 2000, 21:137-152.
12. Koenigs M., Grafman J. The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex. Behav. Brain. Res. 2009, 201:239-243.
13. Korte-Bouws G.A., Korte S.M., De Kloet E.R., Bohus B. Blockade of corticosterone synthesis reduces serotonin turnover in the dorsal hippocampus of the rat as measured by microdialysis. J. Neuroendocrinol. 1996, 8:877-881.
14. Mar A., Spreekmeester E., Rochford J. Antidepressants preferentially enhance habituation to novelty in the olfactory bulbectomized rat. Psychopharmacology (Berl.) 2000, 150:52-60.
15. Martin-Ruiz R., Ugedo L. Electrophysiological evidence for postsynaptic 5-HT(1A) receptor control of dorsal raphe 5-HT neurones. Neuropharmacology 2001, 41:72-78.
16. Masini C.V., Holmes P.V., Freeman K.G., Maki A.C., Edwards G.L. Dopamine overflow is increased in olfactory bulbectomized rats: an in vivo microdialysis study. Physiol. Behav. 2004, 81:111-119.
17. Nestler E.J., Carlezon W.A. The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry 2006, 59:1151-1159.
18. Popik P., Krawczyk M., Golembiowska K., Nowak G., Janowsky A., Skolnick P., Lippa A., Basile A.S. Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102, 677. Cell. Mol. Neurobiol. 2006, 26:857-873.
19. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry 1965, 122:509-522.
20. Skolnick P., Popik P., Janowsky A., Beer B., Lippa A.S. Antidepressant-like actions of DOV 21, 947: a "triple" reuptake inhibitor. Eur. J. Pharmacol. 2003, 461:99-104.
21. Skolnick P., Krieter P., Tizzano J., Basile A., Popik P., Czobor P., Lippa A. Preclinical and clinical pharmacology of DOV 216, 303, a "triple" reuptake inhibitor. CNS Drug Rev. 2006, 12:123-134.
22. Slattery D.A., Markou A., Cryan J.F. Evaluation of reward processes in an animal model of depression. Psychopharmacology (Berl) 2007, 190:555-568.
23. Song C., Leonard B.E. The olfactory bulbectomised rat as a model of depression. Neurosci. Biobehav. Rev. 2005, 29:627-647.
24. Torpey D.C., Klein D.N. Chronic depression: update on classification and treatment. Curr. Psychiatry Rep. 2008, 10:458-464.
25. van der Stelt H.M., Breuer M.E., Olivier B., Westenberg H.G. Permanent deficits in serotonergic functioning of olfactory bulbectomized rats: an in vivo microdialysis study. Biol. Psychiatry 2005, 57:1061-1067.
26. van Riezen H., Leonard B.E. Effects of psychotropic drugs on the behavior and neurochemistry of olfactory bulbectomized rats. Pharmacol. Ther. 1990, 47:21-34.
27. Verhagen L.A., Luijendijk M.C., Korte-Bouws G.A., Korte S.M., Adan R.A. Dopamine and serotonin release in the nucleus accumbens during starvation-induced hyperactivity. Eur. Neuropsychopharmacol. 2009, 19:309-316.
28. Vinkers C.H., Breuer M.E., Westphal K.G., Korte S.M., Oosting R.S., Olivier B., Groenink L. Olfactory bulbectomy induces rapid and stable changes in basal and stress-induced locomotor activity, heart rate and body temperature responses in the home cage. Neuroscience 2009, 159:39-46.
29. Waldinger M.D., Berendsen H.H., Blok B.F., Olivier B., Holstege G. Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: the involvement of the serotonergic system. Behav. Brain. Res. 1998, 92:111-118.